pminews.it

Kolinpharma: third US patent and second for Xinepa

MILAN (AIMnews.it) - The patent for Xinepa relates to the technological process and provides greater opportunities for growth in the U.S. market. It will be valid until September 1, 2036. The US nutraceutical market is expected to reach $133.4b in 2025 compared to $71.7b in 2017.

14/10/2019

pminews.it

Tecno: Allegra Fortunato premiata dall’Institute of Directors come Sustainability Director of the Year 2025

19/11/2025

pminews.it

ICF: 9M25 EBITDA a 7,2 mln ed EBITDA margin al 13,3%

19/11/2025

pminews.it

ICF: stabilimento Robecchetto con Induno ottiene certificazione ZDHC Supplier to Zero – Livello 1

18/11/2025

pminews.it

Tecno: CdA approva il “Regolamento del Piano di Stock Grant Tecno 2025-2027”

18/11/2025